Thoracic Cancer Research

Thoracic Cancer Research

Research into thoracic cancer at Penn State Cancer Institute is conducted by our dedicated thoracic cancer team. See current clinical trials and members of that team here.

Clinical Trials

Repository of Lung Cancer Diagnostic Procedure Images
Piloting a Virtual Navigation (VN) System for Bronchoscopic Tissue Sampling
MATCH Treatment Subprotocol C2: Crizotinib in Patients with Tumors with MET Exon 14 Deletion
MATCH Treatment Subprotocol E: AZD9291 in Patients with Tumors Having EGFR T790M Mutations (Except Non-Small Cell Lung Cancer) or Rare Activating Mutations of EGFR
MATCH Treatment Subprotocol F: Crizotinib in Patients with Tumors (Other Than Adenocarcinoma of Lung or ALCL) with ALK Rearrangements
MATCH Treatment Subprotocol G: Phase II Study of Crizotinib in Patients with ROS1 Translocations (Other Than Patients with Non-Small Cell Lung Cancer)
MATCH Treatment Subprotocol L: Phase II Study of MLN0128 (TAK-228) in Patients with Tumors with mTOR Mutations
MATCH Treatment Subprotocol M: Phase II Study of MLN0128 (TAK-228) in Patients with Tumors with TSC1 or TSC2 Mutations
Development and Validation of a Gene Expression Assay to Predict the Risk of Recurrent Disease in Cutaneous Squamous Cell Carcinoma
Personalized Exercise Oncology (PEXO) - Study
General Protocol for the Acquisition of Whole Blood for the Detection and Characterization of Circulating Tumor Cells and/or Tumor Specific Immunity/Immune Cell Activation for any Malignancy at any Stage of Disease
Oncogenic Mutations/Gene Rearrangements in Patients with Advanced Adenocarcinoma Lung
Characterization of Oncogenic Mutations in Patients with Advanced Squamous Cell Lung Cancer
Oncogenic Driver Mutations/Biomarkers in Screening Participants for Early Detection of Lung Cancer
One Time Tissue and Blood Collection from Patients with Lung Cancer at Risk for Developing Lung Cancer
Tissue and Blood Collection from Patients with Suspected Lung Cancer

Disease Team Members

Research into thoracic cancer at Penn State Cancer Institute is conducted by our dedicated thoracic cancer team. See current clinical trials and members of that team here.
Repository of Lung Cancer Diagnostic Procedure Images
Piloting a Virtual Navigation (VN) System for Bronchoscopic Tissue Sampling
MATCH Treatment Subprotocol C2: Crizotinib in Patients with Tumors with MET Exon 14 Deletion
MATCH Treatment Subprotocol E: AZD9291 in Patients with Tumors Having EGFR T790M Mutations (Except Non-Small Cell Lung Cancer) or Rare Activating Mutations of EGFR
MATCH Treatment Subprotocol F: Crizotinib in Patients with Tumors (Other Than Adenocarcinoma of Lung or ALCL) with ALK Rearrangements
MATCH Treatment Subprotocol G: Phase II Study of Crizotinib in Patients with ROS1 Translocations (Other Than Patients with Non-Small Cell Lung Cancer)
MATCH Treatment Subprotocol L: Phase II Study of MLN0128 (TAK-228) in Patients with Tumors with mTOR Mutations
MATCH Treatment Subprotocol M: Phase II Study of MLN0128 (TAK-228) in Patients with Tumors with TSC1 or TSC2 Mutations
Development and Validation of a Gene Expression Assay to Predict the Risk of Recurrent Disease in Cutaneous Squamous Cell Carcinoma
Personalized Exercise Oncology (PEXO) - Study
General Protocol for the Acquisition of Whole Blood for the Detection and Characterization of Circulating Tumor Cells and/or Tumor Specific Immunity/Immune Cell Activation for any Malignancy at any Stage of Disease
Oncogenic Mutations/Gene Rearrangements in Patients with Advanced Adenocarcinoma Lung
Characterization of Oncogenic Mutations in Patients with Advanced Squamous Cell Lung Cancer
Oncogenic Driver Mutations/Biomarkers in Screening Participants for Early Detection of Lung Cancer
One Time Tissue and Blood Collection from Patients with Lung Cancer at Risk for Developing Lung Cancer
Tissue and Blood Collection from Patients with Suspected Lung Cancer

Clinical Trials Search


Children (age < 18 years)
Adults (age >= 18 years)